for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.O

Latest Trade

98.89USD

Change

-3.16(-3.09%)

Volume

3,700,981

Today's Range

95.80

 - 

103.50

52 Week Range

3.54

 - 

189.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
102.05
Open
102.70
Volume
3,700,981
3M AVG Volume
133.57
Today's High
103.50
Today's Low
95.80
52 Week High
189.40
52 Week Low
3.54
Shares Out (MIL)
61.28
Market Cap (MIL)
6,559.21
Forward P/E
11.78
Dividend (Yield %)
--

Next Event

Novavax Inc Annual Shareholders Meeting

Latest Developments

更多

Novavax Appoints Leadership Team To Advance Nanoflu Through Regulatory Licensure

Endo Announces Fill-Finish Manufacturing And Services Agreement For Novavax Covid-19 Vaccine Candidate

Novavax Initiates Phase 3 Efficacy Trial Of COVID-19 Vaccine In The United Kingdom

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novavax, Inc.

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry

Biotechnology & Drugs

Contact Info

21 Firstfield Rd

GAITHERSBURG, MD

20878-1757

United States

+1.240.2682000

http://www.novavax.com/

Executive Leadership

James Francis Young

Independent Chairman of the Board

Stanley C. Erck

President, Chief Executive Officer, Director

John J. Trizzino

Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer

Gregory M. Glenn

President, Research and Development

Jill Hoyt

Chief Human Resource Officer, Executive Vice President

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

1.2K
EPS (USD)

2017

-12.600

2018

-10.000

2019

-5.510

2020(E)

9.084
Price To Earnings (TTM)
--
Price To Sales (TTM)
130.56
Price To Book (MRQ)
35.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
83.60
LT Debt To Equity (MRQ)
83.60
Return on Investment (TTM)
-21.52
Return on Equity (TTM)
-16.63

Latest News

Latest News

Novavax to explore combined influenza/COVID-19 vaccine for use post pandemic

Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.

UPDATE 1-India's Serum Institute to boost production of COVID-19 vaccine doses to 200 mln

Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said on Tuesday.

FACTBOX-The race for a coronavirus vaccine

More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...

UPDATE 1-Endo starts manufacturing Novavax's potential COVID-19 vaccine

Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.

Novavax signs manufacturing deal with Endo for potential COVID-19 vaccine

Novavax Inc has signed an agreement with Endo International for manufacturing its experimental COVID-19 vaccine, the generic drugmaker said on Friday.

UPDATE 2-Novavax initiates late-stage COVID-19 vaccine trial in UK

Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government's Vaccines Taskforce, sending the company's shares up 6% after the bell.

Novavax starts late-stage COVID-19 vaccine trial in UK

Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in partnership with the UK government's Vaccines Taskforce.

UPDATE 1-Novavax aims for 2 bln COVID-19 vaccine doses with expanded India deal

U.S. drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7%.

Novavax aims for 2 bln COVID-19 vaccine doses with expanded Serum Institute deal

Novavax Inc is doubling its COVID-19 vaccine manufacturing capacity to two billion doses under an agreement with Serum Institute of India, the U.S. company said on Tuesday.

UPDATE 3-Canada wants to be at 'front of line' for coronavirus vaccines, signs deals with Novavax and Johnson & Johnson

Canada reached an agreement in principle on Monday with both Novavax Inc and Johnson & Johnson for millions of doses of their experimental coronavirus vaccines, Prime Minister Justin Trudeau said.

Novavax signs deal for supply of coronavirus vaccines to Canada

Novavax Inc said on Monday it had reached an agreement in principle with Canada to supply up to 76 million doses of its experimental coronavirus vaccine.

UPDATE 1-Novavax begins mid-stage study of COVID-19 vaccine in South Africa

U.S. drug developer Novavax Inc said on Monday it started a mid-stage study of its experimental COVID-19 vaccine in South Africa, as the country experiences a surge in coronavirus cases.

UPDATE 4-Britain lines up more potential COVID-19 vaccine supplies with J&J, Novavax deals

* Over 300 million doses secured to up chances of one that works

CORRECTED-Novavax to deliver 60 mln doses of COVID-19 vaccine candidate to UK

U.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373.

UK buys potential COVID-19 vaccines from J&J and Novavax

The UK government has sealed two more deals to secure COVID-19 vaccines, buying shots in development from U.S. drugmakers Johnson & Johnson and Novavax Inc, the chair of the UK Vaccine Taskforce Katie Bingham told Sky News on Friday.

UPDATE 2- Novavax ties up with SK bioscience to boost supply of potential COVID-19 vaccine

Novavax Inc said on Thursday South Korea's SK bioscience would manufacture a component of the U.S. drug developer's experimental coronavirus vaccine in a bid to boost its supply.

Novavax to work with SK bioscience for coronavirus vaccine component

Novavax Inc said on Thursday South Korea's SK bioscience will manufacture a component of the U.S. drug developer's experimental coronavirus vaccine.

UPDATE 2-Novavax expects it can meet U.S. COVID-19 vaccine demand in 2021, executives say

Novavax Inc's manufacturing capacity is sufficient to meet the U.S. demand for COVID-19 vaccines in 2021, which it believes could be as high as 500 million to 600 million doses, company executives said on Monday.

Takeda to make Novavax's COVID-19 vaccine candidate in Japan

Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two companies said on Friday.

Novavax signs COVID-19 vaccine supply deal with India's Serum Institute

Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up